-
NASDAQ:MNKD +47% on collaborating with United Therapeutics for pulmonary hypertension products.
-
TA +36% on announcing sale of Minit Mart for ~$330.8M to EG Group.
- REPH +25% on planned resubmission of IV meloxicam NDA.
-
CREG +20% on acquiring 20% Ownership of Xi’an Xinhuan.
-
CRIS +11%.
-
CHEK +9% on announcing interim results from its ongoing post-CE approval study of C-Scan system Version 3.
-
CRON +9% on announcing partnership with Ginkgo Bioworks to produce cultured cannabinoids.
-
NBEV +8%.
-
SESN +8%.
-
GERN +7%.
-
CONN +7% on Q2 earnings.
-
SENS +6%.
-
RIGL +6%.
-
BLDP +5% after signing agreement to divest non-core Power Manager business.
-
CANF +5% after providing update on its Phase II clinical trial of Namodenoson (CF102) for the treatment of advanced HCC.
-
PCG +5% after analysts upgrade.